See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Donald Trump
Vladimir Putin
Elon Musk
Israel-Hamas Conflict
Basketball
Premier League
Immigration
CPAC
Vatican
Wrestling
Baseball
Published • loading... • Updated

Sinaptica begins Phase II dual neurostimulation Alzheimer’s study enrolment

Summary by Medical Device Network
Sinaptica Therapeutics has begun enrolling patients in a Phase II trial of its second-generation neuromodulation technology for treating early Alzheimer’s.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Medical Device NetworkMedical Device Network

Sinaptica begins Phase II dual neurostimulation Alzheimer’s study enrolment

Sinaptica Therapeutics has begun enrolling patients in a Phase II trial of its second-generation neuromodulation technology for treating early Alzheimer’s.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medical Device Network broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Alzheimer

Alzheimer

News
For You
Search
BlindspotLocal